- Home
- WHG vs PLX Comparison
WHG vs PLX Comparison
Compare WHG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHG
- PLX
- Stock Information
- Founded
- WHG 1983
- PLX 1993
- Country
- WHG United States
- PLX United States
- Employees
- WHG N/A
- PLX N/A
- Industry
- WHG Investment Managers
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WHG Finance
- PLX Health Care
- Exchange
- WHG Nasdaq
- PLX Nasdaq
- Market Cap
- WHG 151.0M
- PLX 127.4M
- IPO Year
- WHG 2002
- PLX 1998
- Fundamental
- Price
- WHG $17.90
- PLX $1.55
- Analyst Decision
- WHG
- PLX Strong Buy
- Analyst Count
- WHG 0
- PLX 1
- Target Price
- WHG N/A
- PLX $15.00
- AVG Volume (30 Days)
- WHG 10.9K
- PLX 573.2K
- Earning Date
- WHG 08-08-2025
- PLX 08-14-2025
- Dividend Yield
- WHG 3.37%
- PLX N/A
- EPS Growth
- WHG N/A
- PLX N/A
- EPS
- WHG 0.42
- PLX 0.08
- Revenue
- WHG $95,673,000.00
- PLX $61,948,000.00
- Revenue This Year
- WHG N/A
- PLX $14.53
- Revenue Next Year
- WHG N/A
- PLX $75.77
- P/E Ratio
- WHG $43.15
- PLX $20.02
- Revenue Growth
- WHG 5.68
- PLX 62.79
- 52 Week Low
- WHG $12.20
- PLX $0.90
- 52 Week High
- WHG $18.97
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- WHG 52.84
- PLX 47.97
- Support Level
- WHG $17.27
- PLX $1.47
- Resistance Level
- WHG $18.97
- PLX $1.57
- Average True Range (ATR)
- WHG 0.68
- PLX 0.07
- MACD
- WHG -0.04
- PLX -0.00
- Stochastic Oscillator
- WHG 41.53
- PLX 31.82
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.